Bronchiolitis remains the leading cause of hospital admission in infancy and of paediatric intensive care unit use.1 Management of bronchiolitis has been largely limited to supportive care, reflecting ...
A major UK-led clinical trial has found that a treatment commonly used to help premature babies breathe offers no benefit for infants on life support with severe bronchiolitis — a seasonal viral ...
Scientists have developed a new lung surfactant that is produced synthetically rather than relying on the use of animal tissues. With further development, the formulation could provide a cheaper and ...
A major UK-led clinical trial has found that a treatment commonly used to help premature babies breathe offers no benefit for infants on life support ...
Scientists have developed a new lung surfactant that is produced synthetically rather than relying on the use of animal tissues. With further development, the formulation could provide a cheaper and ...
The novel agent molgramostim improved pulmonary gas exchange in autoimmune pulmonary alveolar proteinosis, a randomized trial showed. In this rare condition, surfactant builds up in the alveoli as ...
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced a manuscript titled, ...
A new study from the University of Oklahoma suggests that small genetic differences in two proteins – previously known for their role in premature infants' lungs – may also influence how their eyes ...
Savara Inc. (the "Company") (Nasdaq: SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results